Jefferies initiates Twist Bioscience stock at Hold on valuation
Jefferies initiated coverage on Twist Bioscience (TWST) with a Hold rating and $150 price target, citing premium valuation. The stock trades at $155.65 after a 391% YTD surge. Jefferies notes its market differentiation and AI-driven growth, but warns of high valuation expectations. TWST partners with Eli Lilly's TuneLab for AI/ML drug discovery, while BWS Financial rates it Sell, and Guggenheim reiterates Buy.
How this was made
The 30-second read
Why it matters
Analyst initiation and a lower price target may temper the recent rally, while the Lilly partnership could provide a longer‑term growth catalyst.
Market read
New analyst coverage and partnership news provide fresh data points for traders evaluating Twist Bioscience's valuation and growth outlook.
What to watch
Short‑seller skepticism and the registration of resale shares may introduce dilution risk.
Background
Twist Bioscience is a synthetic DNA manufacturer that has seen a 391% YTD rally. The firm is expanding AI‑driven drug discovery services.
Ticker impact
Jefferies initiated coverage on Twist Bioscience with a Hold rating and a $150 price target, and announced a new partnership with Eli Lilly’s TuneLab.
likely pressure as the market prices in the lower target and valuation concerns
Analyst coverage and a price target below current price typically prompt short‑term selling, especially given the premium valuation noted.
Market effects
Highlights growing AI‑driven demand in synthetic biology, potentially benefiting peers in biotech tools.
U.S. biotech sector may see modest re‑rating activity.
Limited to investors tracking synthetic DNA and AI‑enabled drug discovery.
Counterpoint
The partnership with Eli Lilly could unlock new revenue streams, offsetting valuation concerns.
Key entities
- AnalystJefferies
Initiated coverage with Hold rating and $150 price target.
- PartnerEli Lilly
AI/ML drug discovery platform TuneLab partnering with Twist.
